Centrally acting antiadrenergic (versus unexposed) updated on 03-11-2025

Neonatal bradycardia

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13880
R54302		 Kayser - Methyldopa, 2020 Neonatal bradycardia days before delivery prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified 3.01 [0.86;10.49] C 5/199   5/588 10 199
ref
S13946
R54580		 Fidler - Methyldopa, 1983 Abnormal intrapartum cardiotocograms (mainly Bradycardia) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched 1.02 [0.48;2.15] C 15/49   29/96 44 49
ref
Total 2 studies 1.55 [0.55;4.36] 54 248
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Kayser - Methyldopa, 2020Kayser - Methyldopa, 2020 3.01[0.86; 10.49]1019939%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Fidler - Methyldopa, 1983Fidler - Methyldopa, 1983 1.02[0.48; 2.15]444961%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 53% 1.55[0.55; 4.36]542480.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 2 Tags Adjustment   - No  - No 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 2 Indications Antihypertensive   - All hypertensions, any indications ...  - All hypertensions, any indications or not specified 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 2 MatchedMatched 1.02[0.48; 2.15]4449 -NAFidler - Methyldopa, 1983 1 All studiesAll studies 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.55[0.55; 4.36]5424853%NAKayser - Methyldopa, 2020 Fidler - Methyldopa, 1983 20.510.01.0